Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.76 |
| ▸ | PRKCB | P05771 | 11/20 | 0.76 |
| ▸ | PRKCA | P17252 | 5/20 | 0.66 |
| ▸ | PRKCG | P05129 | 4/20 | 0.66 |
| ▸ | IDH1 | O75874 | 1/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.56 |
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985656 | 0.86 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL13231016 | 0.83 | GSK3B (0.78) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL2984397 | 0.83 | GSK3B (0.82) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL14257784 | 0.82 | GSK3B (0.70) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL4354893 | 0.81 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL14257786 | 0.80 | GSK3B (0.67) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL2984122 | 0.80 | GSK3B (0.76) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL1128129 | 0.80 | GSK3B (0.76) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL2974067 | 0.80 | GSK3B (0.76) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL2987239 | 0.80 | GSK3B (0.76) | GSK3BPRKCBPRKCAPRKCGIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-16 | — | — | US | disclosed |
| US-7524858-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| EP-1900738-A2 | Substituted pyrroline kinase inhibitors | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-7125878-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2006-10-24 | — | — | US | disclosed |
| US-20060205763-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| US-20060205762-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| EP-1506192-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040006095-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMAECUTICA, NV (BE) | 2004-01-08 | — | — | US | disclosed |
| WO-2003095452-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205762-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCA 30/4885 |
| US-20040006095-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCA 30/4885 |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCA 30/4885 |
| US-20060205763-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCA 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.